Neutrophil Extracellular Traps in ANCA-Associated Vasculitis and Interstitial Lung Disease: A Scoping Review.
Miriana d'AlessandroEdoardo ConticiniLaura BergantiniPaolo CameliLuca CantariniBruno FredianiElena BargagliPublished in: Life (Basel, Switzerland) (2022)
Preliminary findings seem to display a lack of efficacy of traditional immunosuppressants, such as Rituximab, in this subset of patients, while to date no patients suffering from a definite ILD have been enrolled in clinical trials. Further insights would be provided by their employment, as a combination treatment, in common clinical practice. Although we can imagine that the inhibition of NETs in patients with AAV-ILD could reduce severity and mortality, we still lack the scientific basis that could improve our understanding of the disease from a molecular point of view.
Keyphrases
- interstitial lung disease
- end stage renal disease
- systemic sclerosis
- clinical trial
- chronic kidney disease
- ejection fraction
- newly diagnosed
- clinical practice
- rheumatoid arthritis
- prognostic factors
- type diabetes
- risk factors
- patient reported outcomes
- idiopathic pulmonary fibrosis
- cardiovascular events
- mental illness
- hodgkin lymphoma
- double blind
- placebo controlled